PharmaEngine, Inc. and Sentinel Oncology Limited enter into an exclusive collaboration and license agreement for SOL-578, a Chk1 inhibitor ... Dec 04
The EMA grants orphan status to medicinal products intended to treat rare disorders that affect fewer than 5 people per 10,000 in the European ... Dec 04
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts... Dec 04
Zydus Cadila, had received an approval from the Drugs Controller General of India to start the Phase 3 clinical trial in COVID-19 patients with ... Dec 04
-Advertisements-